title: Establishment of a quantitative mouse dorsal air sac model and its application to evaluate a new angiogenesis inhibitor.
abstract: We have developed an improved mouse dorsal air sac model for quantifying in vivo tumor-induced angiogenesis. In our improved model, tumor angiogenesis is determined by measuring the blood volume in an area of skin held in contact with a tumor cell-containing chamber, using 51Cr-labeled red blood cells (RBC). The blood volume induced by murine B16-BL6 melanoma cells increased linearly with the cell number in the range from 2 x 10(5) to 5 x 10(6). Ten of 11 human tumor cell lines examined induced a significant increment in blood volume. For three representative human tumor cell lines (A549, WiDr. and HT1080 cells) that showed different angiogenic potencies, the levels of vascular endothelial growth factor (VEGF) produced by the tumor cells cultured under conditions of hypoxia and high cell density were correlated with the degree of in vivo angiogenesis. Using the improved model, it was confirmed that TNP-470, a well-known inhibitor, and borrelidin, an antibiotic from Streptomyces rochei, significantly inhibited the WiDr cell-induced angiogenesis. Borrelidin also inhibited spontaneous lung metastasis of B16-BL6 melanoma at the same dose that inhibited angiogenesis. Our results suggest that the improved mouse dorsal air sac model can be used for simple and quantitative measurement of tumor-induced angiogenesis and its inhibition.
authors.affiliation: Cancer Research Unit, Tsukuba Research Laboratories, Eisai Co. Ltd., Ibaraki, Japan. y-funahashi@hhc.eisai.co.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Funahashi
authors.forename: T
authors.initials: T
authors.lastname: Wakabayashi
authors.forename: T
authors.initials: T
authors.lastname: Semba
authors.forename: J
authors.initials: J
authors.lastname: Sonoda
authors.forename: K
authors.initials: K
authors.lastname: Kitoh
authors.forename: K
authors.initials: K
authors.lastname: Yoshimatsu
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D001810:Blood Volume / Q000187:drug effects; D015179:Colorectal Neoplasms / Q000188:drug therapy; D004353:Drug Evaluation, Preclinical; D016228:Endothelial Growth Factors / Q000378:metabolism*; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000494:pharmacology; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008222:Lymphokines / Q000378:metabolism*; D008546:Melanoma, Experimental / Q000098:blood supply* / Q000378:metabolism / Q000503:physiopathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D009363:Neoplasm Proteins / Q000378:metabolism*; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000503:physiopathology; D014407:Tumor Cells, Cultured; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D016228:Endothelial Growth Factors; D008222:Lymphokines; D009363:Neoplasm Proteins; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D006854:Hydrocortisone